NEW YORK, Feb. 28 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. will hold a conference call on Thursday, March 2, 2006 at 8:30 am EST. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1-800-862-9098 (U.S.), 1-785- 424-1051 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
The press release announcing our financial results for the fourth quarter and year-end 2005 will be posted on the Company’s website, http://www.keryx.com, prior to the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx’s lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life- threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Keryx is also developing additional clinical stage compounds, including Zerenex(TM), which is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease (ESRD) and KRX-0401, a novel, first- in-class oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Ronald C. Renaud, Jr. Chief Financial Officer Keryx Biopharmaceuticals, Inc. 212.531.5965
Keryx Biopharmaceuticals, Inc.
CONTACT: Ronald C. Renaud, Jr., Chief Financial Officer of KeryxBiopharmaceuticals, Inc., +1-212-531-5965
Web site: http://www.keryx.com/
